Clinical Trial Update: A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating siltuximab for high-risk smoldering multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-risk Smoldering Multiple Myeloma

Drugs mentioned

• Siltuximab (siltuximab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: High-risk Smoldering Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2020-01-27